Attached files
| file | filename |
|---|---|
| 10-K - 10-K - SYNERGY PHARMACEUTICALS, INC. | a2202710z10-k.htm |
| EX-4.6 - EX-4.6 - SYNERGY PHARMACEUTICALS, INC. | a2202710zex-4_6.htm |
| EX-32.2 - EX-32.2 - SYNERGY PHARMACEUTICALS, INC. | a2202710zex-32_2.htm |
| EX-31.1 - EX-31.1 - SYNERGY PHARMACEUTICALS, INC. | a2202710zex-31_1.htm |
| EX-10.7 - EX-10.7 - SYNERGY PHARMACEUTICALS, INC. | a2202710zex-10_7.htm |
| EX-32.1 - EX-32.1 - SYNERGY PHARMACEUTICALS, INC. | a2202710zex-32_1.htm |
| EX-31.2 - EX-31.2 - SYNERGY PHARMACEUTICALS, INC. | a2202710zex-31_2.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
Synergy
Pharmaceuticals, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statement on Amendment No. 1 of the Form S-3 (No. 333-163316) of Synergy Pharmaceuticals, Inc. and Subsidiaries (a development stage company) (the "Company") of our reports dated March 16, 2011, relating to the consolidated financial statements and the effectiveness of the Company's internal control over financial reporting which appears in this Form 10-K. Our report on the financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern. Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of the Company's internal control over financial reporting as of December 31, 2010.
/s/
BDO USA, LLP
New York, New York
March 16, 2011